occurred before week 4) and its standard deviation (SD) for each starting dose group were calculated based on this interim data set.
Following initiation of dosing with patiromer, each starting dose group in each stratum demonstrated statistically significant (p <0.001) and clinically meaningful reductions in serum potassium. Mean change from baseline in serum potassium at week 4 or at time of first dose titration, the primary endpoint, ranged from −0.45 to −0.62 mEq/L across the starting dose groups in Stratum 1 and −0.80 to −0.94 mEq/L in Stratum 2. Reductions in serum potassium demonstrated at week 4 were maintained at week 8. At day 3, statistically significant reductions in serum potassium were demonstrated in all dose groups in each stratum, although these reductions were generally smaller than those observed at weeks 1, 4, and 8.
Overall, 4 patients (2%) developed hypokalemia (serum potassium < 3.5 mEq/L) at any time during the treatment phase. In Stratum 1, 2 patients developed hypokalemia (1 in the 8.4 g/day patiromer group and 1 in the 16.8 g/day patiromer group). In Stratum 2, 2 patients developed hypokalemia (both in the 33.6 g/day patiromer group). The hypokalemic event in the 8.4 g/day patiromer group occurred in a patient who was titrated at the day 3 visit from 8.4 g/day to 50.4 g/day patiromer. These observations were consistent with the final analysis.
Overall, patiromer was well tolerated. The most commonly reported AEs included constipation, diarrhea, and vomiting. Safety data from the interim analysis were consistent with that observed in the final analysis.
In the absence of a clear dose-dependent response to patiromer in most of the interim analysis variables, and although in some parameters numerically larger reductions in serum potassium were demonstrated for other dose groups in each stratum, starting at the lowest effective dose is advantageous for the patient since it reduces the potential for side effects, including hypokalemia. For the 8.4 g/day patiromer starting dose, an opportunity for titration in less-responsive patients at day 3, a planned timepoint in the phase 3 study, would reduce the risk of developing a serum potassium level >5.5 mEq/L.
Stability of Serum Potassium at Screening (Cohort 3) and During Run-in (Cohorts 1 and 2)
For the patients in Cohort 3, the results of 2 screening serum potassium measurements are shown in eTable 1. Overall, the mean serum potassium value was 5.38 mEq/L at both prebaseline timepoints.
In cohorts 1 and 2, 1 serum potassium measurement in the predefined hyperkalemia range after starting cohort RAASi treatment was needed for randomization; however, there was a trend for an increase in serum potassium following RAASi initiation in these cohorts.
In these cohorts, the slope of the regression line was examined for evidence of increasing serum potassium. Across all patients in cohorts 1 and 2, the mean (SE) slope was 0.0273 (0.0024) mEq/L per day, corresponding to a mean increase of 0.76 mEq/L serum potassium over a 28-day period.
For the patients in cohorts 1 and 2, patients entered screening normokalemic, started RAASi medication, and were enrolled when their serum potassium exceeded 5.1 mEq/L.
Additional Magnesium Information
No patient developed severe hypomagnesemia (<1.0 mg/dL), while 13 (4.3%) patients had a serum magnesium value <1.2 mg/dL at some time during the 52-week treatment period. Within each stratum, no apparent dose effect was evident when evaluated by starting dose group assignment. No serious treatment emergent adverse events of hypomagnesemia or decreased blood magnesium were reported and no patient discontinued treatment with patiromer because of hypomagnesemia. Overall, in Stratum 1, 47.7% of patients were taking diuretics and 7.3% were taking proton pump inhibitors after baseline during the study, both known to be magnesium-wasting medications. These percentages were increased compared with baseline (43.2% and 3.6%, respectively). In Stratum 2, 54.8% of patients were taking diuretics and 8.3% of patients were taking proton pump inhibitors after baseline during the study. These percentages were also increased compared with baseline; at baseline, 41.7% of patients were taking diuretics and 3.6% were taking proton pump inhibitors. In patients who received magnesium supplements while patiromer was continuing, serum magnesium levels generally increased relative to pre-magnesium supplement values.
Changes in serum magnesium in the 7 patients with sudden cardiac death were not different compared with the whole study population. Time since diabetes diagnosis at screening, mean (SD), y 12.5 (7.3) 12.5 (7.8) 11.4 (6.5) 14.1 (6.5) 13.2 (8.4) 15.6 (9.7)
Time since CKD diagnosis at screening, median (25%-75%), y 2.0 (1.0-3.9) 
